April 1st, 2010 by David Kroll, Ph.D. in Better Health Network, News, Opinion, Research, True Stories
1 Comment »
Have you ever taken an over-the-counter heartburn relief remedy such as Tagamet, Zantac, or Pepcid? How about the beta-blocker atenolol (Tenormin) or metoprolol (Lopressor) for antihypertensive therapy, or the original less-selective beta-blocker propranolol (Inderal) for migraines, presentation anxiety, or stage fright?
If you answered “yes” to either question, you owe a debt of gratitude to Sir James Black, the Scottish physician who left us earlier this week at age 85. The best obituary I have seen memorializing Sir James comes from the UK Telegraph.
Black was called the father of analytical pharmacology and was said to have relieved more human suffering than thousands of doctors could have done in careers spent at the bedside. Certainly, no man on earth earned more for the international pharmaceutical industry. Read more »
*This blog post was originally published at Terra Sigillata*
March 20th, 2010 by David Kroll, Ph.D. in Better Health Network, True Stories
No Comments »
This is a repost of my reflections on my father who passed away 13 years today. It took me 12 years to write the following eulogy and remembrance. While quite personal, I posted it here last year because I felt that my experiences were quite universal, shared by the families of the ten or twenty million alcoholics in the U.S. and the hundreds of millions worldwide. Moreover, I wanted to provide a face for my colleagues who work in the area of substance abuse and a reminder for my clinical colleagues of the people behind those they may dismiss as drunks and junkies.
In becoming one my most most highly-read and highly-commented posts, I thought I would share it again this year, especially for the new readers who’ve come on board in the last twelve months. Read more »
*This blog post was originally published at Terra Sigillata*
March 13th, 2010 by David Kroll, Ph.D. in Better Health Network, True Stories
No Comments »
A few weeks ago, I wrote a post about being stricken with pneumonia and my reflections on what it must be like for people who live continually with chronic illnesses. I was surprised by the response from many readers, quite a few of whom I’ve never seen comment here, who voiced understanding and even relief that a “normal” would take the time to reflect on what their life might be like.
Well, my illness is continuing even longer than my pulmonologist had expected and this has evoked for me a whole new layer of emotions. I write the following not for sympathy or concern, but rather for the Medicine and Health channel of ScienceBlogs to give voice to those much worse off than I who may not otherwise have a voice in our national health care dialogue. Read more »
*This blog post was originally published at Terra Sigillata*
March 1st, 2010 by David Kroll, Ph.D. in Better Health Network, News
2 Comments »
A year ago we wrote about a death of a San Jose teenager from poisoning by hydrogen sulfide gas, or H2S. At the time, I had hypothesized that the death might have been from an attempt at synthesizing methamphetamine gone awry.
But while one can mistakenly generate hydrogen sulfide gas from improper meth synthesis, I soon learned that intentional suicides with H2S is an increasing US trend imported from Japan. One can easily mix commonly-available consumer products to generate the gas and high enough concentrations can cause death. The gas acts in a manner similar to cyanide by binding to the heme in cytochrome c oxidase and inhibiting electron transport and ATP production by oxidative phosphorylation in the mitochondria. (Interestingly, small amounts of H2S are made in the body and is being investigated as a neurotransmitter and biological modulator.) Read more »
*This blog post was originally published at Terra Sigillata*
February 23rd, 2010 by David Kroll, Ph.D. in Better Health Network, News, Research
1 Comment »
Just a quick post on an article that caught my eye: Jazz Pharmaceuticals of Palo Alto, CA, has announced that the US FDA has accepted their new drug application (NDA) filing for JZP-6, or sodium oxybate, for the treatment of pain and fatigue associated with fibromyalgia.
The NDA was based on positive outcomes of two, Phase III clinical trials – those randomized, placebo-controlled double-blind trials that serve as the gold standard for drug efficacy. The company expects an approval decision from FDA by October 2010. Read more »
*This blog post was originally published at Terra Sigillata*
